AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04321590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)
Description: Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks
Study NCT00994890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Description: Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
Study NCT00994890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Description: Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
Study NCT00994890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg
Description: Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
Study NCT03323385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: Once Daily
Study NCT03323385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once Daily
Study NCT00890201 — intervention group
Intervention type: PROCEDURE
Intervention: Gallbladder bile sampling and intraoperative cholangiography
Description: Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished
Study NCT02347202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online counseling via Zoom teleconferencing
Study NCT02347202 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telephone support as needed
Study NCT02928029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Sequential dose escalation in Intravenous (IV) injection
Study NCT02928029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02928029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
Study NCT02928029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
Study NCT02928029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is administered orally at 40 mg
Study NCT02928029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is administered orally at 40 mg
Study NCT01118884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
Study NCT04690556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis (ranibizumab)
Description: Lucentis® 0.5 mg via intravitreal injection once monthly
Study NCT04690556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUBT010 (proposed ranibizumab biosimilar)
Description: LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly
Study NCT04423224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GDFM
Description: Stroke volume variation fluid management
Study NCT04423224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: USUAL CARE - CONTROL
Description: Usual care fluid management
Study NCT00472823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Orally for one year
Study NCT00472823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Orally for one year
Study NCT00472823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate (Citracal)
Description: Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
Study NCT02287363 — intervention group
Intervention type: OTHER
Intervention: No intervention involved
Description: No interventions will be involved since it is an observational study
Study NCT04005781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
Study NCT04005781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
Study NCT04733664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFI using the FAST PV Technology
Description: The bolus IV administered visible fluorescent injectate (VFI) agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
Study NCT02067546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental toilet seat
Study NCT02067546 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard toilet seat
Study NCT03770728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide SAR439977
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT03770728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT03770728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy: Metformin alone or in combination with SU
Description: Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.
Study NCT03770728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background therapy: Metformin alone or in combination with SU
Description: Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.
Study NCT01574898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0474 - A mg
Description: Single oral administration
Study NCT01574898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0474 - B mg
Description: Single oral administration
Study NCT01574898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0474 - C mg
Description: Single oral administration
Study NCT01574898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: V0018 - B mg
Description: Single oral administration
Study NCT01574898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niquitin® Fresh Mint 4 mg
Description: Single oral administration
Study NCT04979897 — intervention group
Intervention type: OTHER
Intervention: Intensive care unit stay during the COVID-19 pandemic
Description: Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open \[close\] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study
Study NCT02306291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Description: E-selectin antagonist
Study NCT02306291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: induction chemotherapy
Study NCT02306291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: induction chemotherapy
Study NCT02306291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: induction chemotherapy
Study NCT02306291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: induction chemotherapy
Study NCT00805649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low fluorescence Photodynamic therapy
Description: 42 J/cm2 for 72 sec
Study NCT00805649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core pars plana vitrectomy
Description: 24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
Study NCT00805649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: intravitreal injection of 0.8 mg dexamethasone
Study NCT00805649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravitreal injection of 1.25 mg bevacizumab
Study NCT00805649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core pars plana vitrectomy
Description: 0.4 mL core pars plana vitrectomy
Study NCT00805649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcincolone
Description: intravitreal injection of 8 mg triamcincolone
Study NCT01930487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement with antioxidants
Description: Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
Study NCT01930487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
Study NCT01833793 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel IUD (Mirena, BAY86-5028)
Description: Women who have been prescribed Mirena in contraception; followed up for 12 months
Study NCT05488028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezo-electric surgery of impacted lower third molars
Description: During lower third molar surgery, osteotomy is performed using piezoelectric instrumentation.~When necessary, tooth sectioning was performed with a high-speed tungsten carbide slit drill under saline irrigation and the tooth removed in single or multiple segments.
Study NCT05488028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotary bur surgery of impacted lower third molars
Description: During lower third molar surgery, osteotomy is performed using rotary instruments
Study NCT02366715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeatedHumidifiedHighFlowNasalCannula
Description: We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. \[3\] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.~Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016.
Study NCT02020213 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Posaconazole
Description: 400 mg po bid for 8 weeks
Study NCT04999319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVB
Description: Paravertebral block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
Study NCT04999319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB
Description: Erector spinae plane block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
Study NCT04360291 — intervention group
Intervention type: OTHER
Intervention: Eye tracker
Description: In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded
Study NCT00779181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX415
Description: ADX415 taken three times a day to achieve a high total daily dose
Study NCT00779181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX415
Description: ADX415 taken three times a day to achieve a mid level total daily dose
Study NCT00779181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX415
Description: ADX415 taken three times a day to achieve a low total daily dose
Study NCT00779181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken three times a day
Study NCT03796923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early follow-up visit after discharge
Description: Early follow-up visit and different degrees of specialized care after discharge
Study NCT03796923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early follow-up visit after discharge
Description: Early follow-up visit and different degrees of specialized care after discharge
Study NCT03796923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive geriatric assessment (CGA)
Description: Comprehensive geriatric assessment (CGA) during admission
Study NCT03796923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Description: Comprehensive geriatric assessment (CGA) during admission
Study NCT01957735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP31510 monotherapy
Study NCT01957735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BP31510 in combination with chemotherapy
Study NCT00954668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate angiography and revascularization
Description: immediate angiography \< 2 hours after randomization
Study NCT00954668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early invasive angiography
Description: early invasive angiography 12-72 h after randomization
Study NCT00348907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thermal cure
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
Study NCT00348907 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: late thermal cure
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
Study NCT03796923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continued geriatric care
Description: Continued specialized geriatric care after discharge
Study NCT03796923 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Possible follow-up visit from GP
Description: Usual care: follow up visit from GP within one week after discharge
Study NCT01177826 — intervention group
Intervention type: PROCEDURE
Intervention: Sample collection
Description: Stool sample
Study NCT01992900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurartesim dispersible oral tablet
Description: The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.
Study NCT01992900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eurartesim film coated tablet
Description: The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
Study NCT02569645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
Study NCT02920034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency denervation of the main renal arteries
Description: Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)
Study NCT02920034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation of renal arteries and branches
Description: Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
Study NCT02591511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart phone and pad
Description: Smart phone and pad is the mobile include the smart phone and pad, that can download the APP from internet.
Study NCT02591511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stroke-related health education manual
Description: stroke-related health education manual is the manual mainly contained information regarding the prevention of stroke risk factors.
Study NCT03254849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 1 tablet
Study NCT03254849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Description: 1 tablet
Study NCT06118190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: All participants treated with procaine and lidocaine injection for treatment.
Study NCT01392391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Task Oriented Exercise Training
Description: Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.~Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines
Study NCT01392391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Care Get with the Guidelines
Description: Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica
Study NCT02449915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
Study NCT02449915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
Study NCT02804685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise protocol
Description: The multi-intervention exercise protocol consists in a performance of agility, strength and balance exercises. It has to be fulfilled during 6 weeks (twice a week) before the regular training performance. The exercises should be done for almost 15 minutes approx. There will be 6 exercises in total: squat with toe raise, one-leg squats, single-leg balance (throwing a ball with a partner), vertical jumps, hamstring exercise, quick forwards and backwards sprints.
Study NCT03307213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom™ CoCr Biolimus A9™ stent
Description: Stent implantation
Study NCT03307213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioFreedom™ SS Biolimus A9™ stent
Description: Stent implantation
Study NCT02920034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound denervation of the main renal arteries
Description: Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
Study NCT03884803 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: E-health website
Description: Access to the e-health intervention (website)
Study NCT03884803 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Control group to continue with standard care
Study NCT01949792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptacog alfa (activated)
Description: Subject will receive a single injection (i.v.) of 270 microg/kg rFVIIa (NovoSeven®)
Study NCT01949792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptacog alfa (activated)
Description: Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa (NovoSeven®) over a 6 hour period (each injection will be separated by 3 hours)